X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Novo Nordisk, through a subsidiary, will initiate a tender offer to acquire all outstanding shares of Dicerna common stock and will initiate the development of DCR-NOVO1.
Lead Product(s): DCR-NOVO1
Therapeutic Area: Cardiology/Vascular Diseases Product Name: DCR-NOVO1
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: $3,300.0 million Upfront Cash: $3,300.0 million
Deal Type: Acquisition November 18, 2021
Details:
Phase 1 data demonstrated the safety and tolerability of single ascending doses of belcesiran in healthy volunteers (up to and including the final 12 mg/kg dose cohort) and further reaffirming the dosing regimen established for the ESTRELLA Phase 2 study of belcesiran.
Lead Product(s): Belcesiran
Therapeutic Area: Genetic Disease Product Name: GalXC
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2021
Details:
PHYOX2 trial data underscore the potential of DCR-PHXC (Nedosiran), a Hepatic lactate dehydrogenase enzyme inhibitor, will be a meaningful treatment option for those affected by Primary Hyperoxaluria 1, if approved.
Lead Product(s): Nedosiran
Therapeutic Area: Genetic Disease Product Name: DCR-PHXC
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2021
Details:
Nedosiran, a late-stage investigational GalXC™ RNAi therapeutic candidate demonstrated safety and tolerability results in PHYOX4 trial consistent with previously reported studies in the PHYOX clinical development program for primary hyperoxaluria (PH).
Lead Product(s): Nedosiran
Therapeutic Area: Genetic Disease Product Name: DCR-PHXC
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2021
Details:
Dicerna’s announced that it dosed first subjects in its Phase 1 clinical trial to assess DCR-AUD, an investigational GalXC™ RNAi therapeutic in development for the treatment of alcohol use disorder (AUD).
Lead Product(s): DCR-A1203
Therapeutic Area: Psychiatry/Psychology Product Name: DCR-AUD
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
Details:
Nedosiran achieved the primary endpoint in the PHYOX2 trial, demonstrating a statistically significant reduction from baseline in urinary oxalate (Uox) excretion compared to placebo (p<0.0001).
Lead Product(s): Nedosiran
Therapeutic Area: Genetic Disease Product Name: DCR-PHXC
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Veristat
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2021
Details:
Nedosiran achieved the primary endpoint in the PHYOX2 trial, demonstrating a statistically significant reduction from baseline in urinary oxalate (Uox) excretion compared to placebo (p<0.0001).
Lead Product(s): Nedosiran
Therapeutic Area: Genetic Disease Product Name: DCR-PHXC
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2021
Details:
The ESTRELLA clinical trial is part of Dicerna’s SHINE clinical development program to evaluate the safety and efficacy of belcesiran, formerly known as DCR-A1AT, for the treatment of AATLD.
Lead Product(s): Belcesiran
Therapeutic Area: Genetic Disease Product Name: GalXC
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2021
Details:
Boehringer Ingelheim has accepted a GalXC™ RNAi candidate for advancement under an existing agreement for the discovery and development of novel therapies for the treatment of chronic liver diseases. DCR-LIV2 will be investigated for the treatment of NASH.
Lead Product(s): DCR-LIV2
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: DCR-LIV2
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: $170.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration May 24, 2021
Details:
Dicerna became entitled to royalties on worldwide net product sales of OXLUMO as part of a 2020 non-exclusive intellectual property cross-license agreement between Dicerna and Alnylam related to the companies’ PH programs.
Lead Product(s): Lumasiran
Therapeutic Area: Genetic Disease Product Name: Oxlumo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Royalty Pharma
Deal Size: $240.0 million Upfront Cash: $180.0 million
Deal Type: Acquisition April 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
